Glaucoma Market to Observe Impressive Growth During the Forecast Period (2024-2034), Evaluates DelveInsight | Bayer, SPARC, Laboratories Sophia, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire

The Glaucoma Market size was valued approximately USD 4,073 million in 2022 and report offers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the 7MM.
DelveInsight's "Glaucoma Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Glaucoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glaucoma Market Forecast [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Glaucoma Market Report:

* The Glaucoma market size was valued approximately USD 4,073 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In June 2023, Ciliatech's implantable device for glaucoma patients is nearing regulatory approval following the disclosure of favorable outcomes from a subsequent two-year post-operative clinical trial.
* In 2022, the Glaucoma market in the US stood out with the highest market size, reaching USD 2,571 million in net sales revenue among the 7MM. Conversely, the UK exhibited the lowest market size, with approximately USD 132 million.
* In 2022, it was estimated that there were approximately 7,045,443 diagnosed prevalent cases of Glaucoma in the 7MM. However, the total burden of Glaucoma, including both diagnosed and undiagnosed cases, was estimated to be around 16,632,421 in the same year across the 7MM.
* The overall Glaucoma market size is projected to increase in the forecast period, driven by the anticipated introduction of emerging therapies such as iDose TR (travoprost intraocular implant), NCX 470, PDP-71, and other treatments.
* Glaucoma often goes unnoticed in a majority of patients due to various factors. DelveInsight's estimates indicate that out of the 16,632,421 prevalent Glaucoma cases in the 7MM in 2022, only around 7,045,443 cases are believed to have been formally diagnosed.
* Key Glaucoma Companies: SPARC, Laboratories Sophia, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire Pharma, Kowa, Bayer, Alcon Research, Pfizer, Merck Sharp & Dohme LLC, Quark Pharmaceuticals, and others
* Key Glaucoma Therapies: PDP-716, PRO-122, EYBELIS/Omidenepag isopropyl/DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, Aflibercept (Eylea, BAY 86-5321), Travoprost, timolol/dorzolamide, QPI-1007, and others
* Glaucoma can impact individuals of both genders, but the ratio of male to female Glaucoma patients indicates a higher prevalence among females. In 2022, there were approximately 3,234,796 cases of Glaucoma among males and 3,810,646 cases among females.
* The Glaucoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glaucoma pipeline products will significantly revolutionize the Glaucoma market dynamics.

Glaucoma Overview

Glaucoma is a disease that damages the eye's optic nerve. It usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in eye, damaging the optic nerve. The condition is a leading cause of blindness for people over 60 years old. But blindness from glaucoma can often be prevented with early treatment. There are two main types of glaucoma - primary and secondary

Get a Free sample for the Glaucoma Market Report:

https://www.delveinsight.com/report-store/glaucoma-market [https://www.delveinsight.com/report-store/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Glaucoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Glaucoma Epidemiology Segmentation:

The Glaucoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

* Total Prevalence of Glaucoma
* Prevalent Cases of Glaucoma by severity
* Gender-specific Prevalence of Glaucoma
* Diagnosed Cases of Episodic and Chronic Glaucoma

Download the report to understand which factors are driving Glaucoma epidemiology trends @ Glaucoma Epidemiology Forecast [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Glaucoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glaucoma market or expected to get launched during the study period. The analysis covers Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Glaucoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Glaucoma Therapies and Key Companies

* NCX-470: Nicox Ophthalmics
* TRS01: Tarsier Pharma
* PDP-716: SPARC
* PRO-122: Laboratories Sophia
* EYBELIS/Omidenepag isopropyl/DE-117: Santen Pharmaceutical
* DE-130A: Santen Pharmaceutical
* Sepetaprost (DE-126/ONO9054): Santen Pharmaceutical
* Nyxol: Ocuphire Pharma
* K-232: Kowa
* Aflibercept (Eylea, BAY 86-5321): Bayer
* Travoprost: Alcon Research
* Timolol: Pfizer
* timolol/dorzolamide: Merck Sharp & Dohme LLC
* QPI-1007: Quark Pharmaceuticals

Discover more about therapies set to grab major Glaucoma market share @ Glaucoma Treatment Market [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Glaucoma Market Drivers

* Rich emerging pipeline
* Development of advanced antiglaucoma medications
* Development of treatment methods to tackle the situation of non-adherence
* Patients-friendly dosage regimes
* Rise in awareness

Glaucoma Market Barriers

* Approaches to clinical practice
* Socioeconomic barriers
* Lack of patient pool due to under diagnosis

Scope of the Glaucoma Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Glaucoma Companies: SPARC, Laboratories Sophia, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire Pharma, Kowa, Bayer, Alcon Research, Pfizer, Merck Sharp & Dohme LLC, Quark Pharmaceuticals, and others
* Key Glaucoma Therapies: PDP-716, PRO-122, EYBELIS/Omidenepag isopropyl/DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, Aflibercept (Eylea, BAY 86-5321), Travoprost, timolol/dorzolamide, QPI-1007, and others
* Glaucoma Therapeutic Assessment: Glaucoma current marketed and Glaucoma emerging therapies
* Glaucoma Market Dynamics: Glaucoma market drivers and Glaucoma market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Glaucoma Unmet Needs, KOL's views, Analyst's views, Glaucoma Market Access and Reimbursement

To know more about Glaucoma companies working in the treatment market, visit @ Glaucoma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Glaucoma Market Report Introduction

2. Executive Summary for Glaucoma

3. SWOT analysis of Glaucoma

4. Glaucoma Patient Share (%) Overview at a Glance

5. Glaucoma Market Overview at a Glance

6. Glaucoma Disease Background and Overview

7. Glaucoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Glaucoma

9. Glaucoma Current Treatment and Medical Practices

10. Glaucoma Unmet Needs

11. Glaucoma Emerging Therapies

12. Glaucoma Market Outlook

13. Country-Wise Glaucoma Market Analysis (2020-2034)

14. Glaucoma Market Access and Reimbursement of Therapies

15. Glaucoma Market Drivers

16. Glaucoma Market Barriers

17. Glaucoma Appendix

18. Glaucoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glaucoma-market-to-observe-impressive-growth-during-the-forecast-period-20242034-evaluates-delveinsight-bayer-sparc-laboratories-sophia-santen-pharmaceutical-nicox-ophthalmics-ocuphire]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.